Enhanced In Vivo activation of Adoptively Transferred Genetically Targeted T Cells Following Cyclophosphamide Chemotherapy: Initial Results From a Phase I Clinical Trial Treating CLL Patients with Autologous CD19-Targeted T Cells

被引：0
|
作者：
Brentjens, Renier J. [1 ]
Hollyman, Daniel [1 ]
Park, Jae [1 ]
Santos, Elmer [1 ]
Yeh, Raymond [1 ]
Stefanski, Jolanta [1 ]
Taylor, Clare [1 ]
Weiss, Mark A. [1 ]
Filippa, Daniel [1 ]
Riviere, Isabelle [1 ]
Sadelain, Michel W. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1335 / 1335
页数：1
相关论文
共 50 条
  • [1] Unexpected Toxicity of Cyclophosphamide Followed by Adoptively Transferred CD19-Targeted T Cells in a Patient with Bulky CLL
    Brentjens, Renier J.
    Riviere, Isabelle
    Hollyman, Daniel
    Taylor, Clare
    Nikhamin, Yan
    Stefanski, Jolanta
    Lee, James
    Yeh, Raymond
    Santos, Elmer
    Sadelain, Michel
    MOLECULAR THERAPY, 2009, 17 : S157 - S157
  • [2] Impact of the Conditioning Chemotherapy On Outcomes in Adoptive T Cell Therapy: Results From a Phase I Clinical Trial of Autologous CD19-Targeted T Cells for Patients with Relapsed CLL
    Park, Jae H.
    Riviere, Isabelle
    Wang, Xiuyan
    Stefanski, Jolanta
    He, Qing
    Taylor, Clare
    Olszewska, Malgorzata
    Wasielewska, Teresa
    Bartido, Shirley
    Davila, Marco L.
    Bernal, Yvette
    Lamanna, Nicole
    Noy, Ariela
    Sadelain, Michel
    Brentjens, Renier J.
    BLOOD, 2012, 120 (21)
  • [3] Updated results: phase I trial of autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy.
    Geyer, Mark Blaine
    Park, Jae Hong
    Riviere, Isabelle
    Wang, Xiuyan
    Purdon, Terence
    Sadelain, Michel
    Brentjens, Renier J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
    Brentjens, Renier J.
    Riviere, Isabelle
    Park, Jae H.
    Davila, Marco L.
    Wang, Xiuyan
    Stefanski, Jolanta
    Taylor, Clare
    Yeh, Raymond
    Bartido, Shirley
    Borquez-Ojeda, Oriana
    Olszewska, Malgorzata
    Bernal, Yvette
    Pegram, Hollie
    Przybylowski, Mark
    Hollyman, Daniel
    Usachenko, Yelena
    Pirraglia, Domenick
    Hosey, James
    Santos, Elmer
    Halton, Elizabeth
    Maslak, Peter
    Scheinberg, David
    Jurcic, Joseph
    Heaney, Mark
    Heller, Glenn
    Frattini, Mark
    Sadelain, Michel
    BLOOD, 2011, 118 (18) : 4817 - 4828
  • [5] Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy
    Geyer, Mark B.
    Riviere, Isabelle
    Senechal, Brigitte
    Wang, Xiuyan
    Wang, Yongzeng
    Purdon, Terence J.
    Hsu, Meier
    Devlin, Sean M.
    Halton, Elizabeth
    Lamanna, Nicole
    Rademaker, Jurgen
    Sadelain, Michel
    Brentjens, Renier J.
    Park, Jae H.
    MOLECULAR THERAPY, 2018, 26 (08) : 1896 - 1905
  • [6] Phase I Clinical Trial of Autologous CD19-Targeted 19-28z CAR T Cells in Adult Patients With Relapsed or Refractory B-ALL
    Park, Jae H.
    Riviere, Isabelle
    Wang, Xiuyan
    Bernal, Yvette
    Halton, Elizabeth
    Quintanilla, Hilda
    Curran, Kevin
    Sauter, Craig
    Sadelain, Michel
    Brentjens, Renier J.
    MOLECULAR THERAPY, 2015, 23 : S188 - S189
  • [7] Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL
    Geyer, Mark B.
    Riviere, Isabelle
    Senechal, Brigitte
    Wang, Xiuyan
    Wang, Yongzeng
    Purdon, Terence J.
    Hsu, Meier
    Devlin, Sean M.
    Palomba, M. Lia
    Halton, Elizabeth
    Bernal, Yvette
    van Leeuwen, Dayenne G.
    Sadelain, Michel
    Park, Jae H.
    Brentjens, Renier J.
    JCI INSIGHT, 2019, 4 (09)
  • [8] CD19-Targeted Normal and CLL Patient T Cells Expanded with Beads Can Eradicate Systemic Tumors In Vivo
    Stefanski, J.
    Brentjens, R.
    Hollyman, D.
    Bonyhadi, M.
    Sadelain, M.
    Riviere, I.
    MOLECULAR THERAPY, 2006, 13 : S102 - S102
  • [9] A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia
    Enblad, Gunilla
    Karlsson, Hannah
    Gammelgard, Gustav
    Wenthe, Jessica
    Lovgren, Tanja
    Amini, Rose Marie
    Wikstrom, Kristina I.
    Essand, Magnus
    Savoldo, Barbara
    Hallbook, Helene
    Hoglund, Martin
    Dotti, Gianpietro
    Brenner, Malcolm K.
    Hagberg, Hans
    Loskog, Angelica
    CLINICAL CANCER RESEARCH, 2018, 24 (24) : 6185 - 6194
  • [10] Phase I Trial Of Autologous CD19-Targeted CAR-Modified T Cells As Consolidation After Purine Analog-Based First-Line Therapy In Patients With Previously Untreated CLL
    Park, Jae H.
    Riviere, Isabelle
    Wang, Xiuyan
    Stefanski, Jolanta
    He, Qing
    Borquez-Ojeda, Oriana
    Wasielewska, Teresa
    Taylor, Clare
    Qu, Jinrong
    Bartido, Shirley
    Bernal, Yvette J.
    Sadelain, Michel
    Brentjens, Renier J.
    BLOOD, 2013, 122 (21)
12345